Table 1.

Candidate AIDS restriction genes

Year	Gene symbol	Allele	Mode	Effect	Citation(s)
1996	CCR5	Δ32	Recessive	Prevents infection	[12-14]
1996	CCR5	Δ32	Dominant	Delays AIDS	[12]
1997	CCR2	64I	Dominant	Delays AIDS	[80]
1998	CCR5P	P1	Recessive	Accelerates AIDS	[81]
1998	SDF1	3'A	Recessive	Delays AIDS	[82]
1999	CCR5	Δ32	Dominant	Prevents lymphoma	[15]
1999	HLA	A,B,C,'Homozy'	Co-dominant	Accelerates AIDS	[83]
2000	IL10	5'A	Dominant	Limits infection	[84]
	IL10	5'A	Dominant	Accelerates AIDS	[84]
2001	HLA	B*35Px	Co-dominant	Accelerates AIDS	[85]
2002	RANTES	-403A	Dominant	Accelerates AIDS	[86]
		In1.1C	Co-dominant	Accelerates AIDS	[86]
2002	KIR	3DS1	Epistatic	Delays AIDS	[28,29]
			(Bw4-801)
2003	EOTAXIN-MCP1	Hap7	Dominant	Enhances infection	[87]
2003	HLA	B*57	Co-dominant	Delays AIDS	[88]
2003	IFNG	179T	Dominant	Accelerates AIDS	[89]
2003	CXCR6	E3K	Dominant	Accelerates PCP	[90]
2004	APOBEC3G	H186R	Recessive	Accelerates AIDS	[91]
2004	DCSIGN	-336T	Dominant	Decreases infection	[92]
2006	HLA	B27	Co-dominant	Delays AIDS	[93]
2006	TSG101	Hap2	Dominant	Accelerates AIDS	[94]
2006	TRIM5	Hap4	Dominant	Increases infection	[95]
2007	CUL5	HapI	Co-dominant	Accelerates CD4 loss	[96]
2007	PP1A (cyclophilin A)	SNP-4	Dominant	Accelerates AIDS	[97]
2007	HLA	Bw4	Dominant	Reduces HIV	[98]
				Transmission
2008	MYH9			End Stage Renal Disease	[31]
2008	MYH9			HIV FSGN	[30]
2008	mtDNA	Hap-J, U5a	Dominant	Accelerates AIDS	[56]
2008	mtDNA	Hap-H	Dominant	Increases	[55]
				Lipoatrophy post
				HAART
2008	mtDNA	Hap-J	Dominant	Delays CMV-NRD	[99]
2009	HCP5	T>G; rs2395029	Dominant	HIV set point	[33]
2009	HLA	rs9264942	Dominant	HIV set point	[33]
2009	PROX1	Hap-CGT	Recessive	Delays AIDS progression	[37]
2009	APOBEC 3B	ΔV_	Recessive	Increases infection	[100]
2010	PECI	G	Dominant	Accelerates AIDS	[52]
2010	ACSM4	A	Co-dominant	Delays AIDS	[52]
2010	NCOR2	T	Dominant	Increases infection	[57]
2010	IDH1	C	Dominant	Prevents infection	[57]

All these genes were discovered or validated using the NCI-Laboratory of Genomic Diversity. Eight AIDS cohorts comprising more than 10,000 study participants were used in these studies from 1985 to 2011 [5,10,79,101].